These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 26333236

  • 1. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
    Kesselheim AS, Darrow JJ.
    Yale J Health Policy Law Ethics; 2015; 15(2):293-347. PubMed ID: 26333236
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB.
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract] [Full Text] [Related]

  • 5. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 6. Access before approval--a right to take experimental drugs?
    Okie S.
    N Engl J Med; 2006 Aug 03; 355(5):437-40. PubMed ID: 16885545
    [No Abstract] [Full Text] [Related]

  • 7. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
    Khullar D, Ohn JA, Trusheim M, Bach PB.
    N Engl J Med; 2020 Jan 30; 382(5):473-480. PubMed ID: 31995697
    [No Abstract] [Full Text] [Related]

  • 8. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ.
    Food Drug Law J; 1999 Jan 30; 54(2):187-94. PubMed ID: 11758572
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL.
    Duke Law J; 2013 Feb 30; 62(5):1069-108. PubMed ID: 25330553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ, Avorn J, Kesselheim AS.
    JAMA; 2020 Jan 14; 323(2):164-176. PubMed ID: 31935033
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM, Kesselheim AS.
    N Engl J Med; 2008 Feb 21; 358(8):843-9. PubMed ID: 18287608
    [No Abstract] [Full Text] [Related]

  • 18. Correcting Hatch-Waxman.
    Fernandes M.
    Health Aff (Millwood); 2008 Feb 21; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A, Lauterio TJ, Davis MW.
    Adv Ther; 2011 Oct 21; 28(10):842-56. PubMed ID: 21894470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.